Phase 3 Trial Results: Efficacy and Safety of Elagolix in a Subset of Women with Uterine Fibroids and Adenomyosis

Ozgul Muneyyirci‐Delale, Archer Df, JHJ Kim, R Liu, C. Owens, Elizabeth E. Puscheck
In: Journal of Minimally Invasive Gynecology · 2019 · vol. 26(7) , pp. S41 · doi:10.1016/j.jmig.2019.09.580 · W2980812342
article OA: closed CC0 ⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This Phase 3 trial assessed the efficacy and safety of elagolix in women with uterine fibroids and adenomyosis, reporting outcomes for a specific subset of participants.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

adenomyosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK